TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6478738
Drug: Diazepam 40
Normalized name: Diazepam 400 microgram/mL oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 40 mg + Methadone 150% of maintenance dose
Study: 6478738
Drug: Methadone 100%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone 100% of maintenance dose
Study: 6478738
Drug: Methadone 150%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone 150% of maintenance dose
Study: 6478738
Drug: Methadone 200%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone 200% of maintenance dose
Study: 30734266
Drug: mirikizumab 30
Normalized name: Mirikizumab
DrugBank: Mirikizumab (DB14910)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mirikizumab 30 mg
Study: 30734266
Drug: mirikizumab 100
Normalized name: mirikizumab 100 mg in 1 mL SUBCUTANEOUS INJECTION, SOLUTION [Omvoh]
Approvals — FDA: no, EMA: no, PMDA: no
Description: mirikizumab 100 mg
Study: 30734266
Drug: mirikizumab 300
Normalized name: Mirikizumab
DrugBank: Mirikizumab (DB14910)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mirikizumab 300 mg
Study: 17869596
Drug: Levobupivacaine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine infusion (16.25mg/h for 24h)
Study: 11448018
Drug: 66 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 66 mg/day etidronate
Study: 11448018
Drug: 133 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 133 mg/day etidronate
Study: 11448018
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day etidronate
Study: 8040990
Drug: 99mTc MIBI
Normalized name: 99mTc medronate
DrugBank: Technetium Tc-99m medronate (DB09138)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 99mTc MIBI injection during stress testing
Study: 17709433
Drug: Refined olive
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refined olive oil (50 g/m² body surface area)
Study: 17709433
Drug: High-palmitic sunflower
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-palmitic sunflower oil (50 g/m² body surface area)
Study: 17709433
Drug: Butter (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butter (50 g/m² body surface area)
Study: 17709433
Drug: Mixture of
Normalized name: OCTADECANOL (MIXTURE OF ISOMERS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixture of vegetable and fish oils (50 g/m² body surface area)
Study: 28375706
Drug: Diabetes without
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetes without metformin treatment
Study: 28375706
Drug: Diabetes with
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetes with metformin treatment
Study: 15153664
Drug: Fluvastatin 20
Normalized name: fluvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 20 mg once daily for 12 weeks
Study: 11286302
Drug: Oral trimetazidine
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral trimetazidine
Study: 8900987
Drug: Inflated G-suit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inflated G-suit (50 mm Hg)
Study: 8900987
Drug: Non-inflated G-suit
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-inflated G-suit
Study: 8900987
Drug: Without G-suit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Without G-suit
Study: 28650087
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health educational strategy (OHES) and Atraumatic Restorative Treatment (ART) restoration
Study: 28650087
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health educational strategy (OHES)
Study: 25866155
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g of Lentinula edodes (shiitake) mushrooms daily
Study: 25866155
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of Lentinula edodes (shiitake) mushrooms daily
Study: 24525232
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (methotrexate, vinblastine, doxorubicin, cisplatin)
Study: 10394686
Drug: Dihydroergocristine 3
Normalized name: dihydroergocristine 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergocristine 3 mg + Piracetam 1.6 g every 12 hours for 90 days
Study: 10394686
Drug: Dihydroergocristine 1.5
Normalized name: dihydroergocristine 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergocristine 1.5 mg + Piracetam 0.8 g every 8 hours for 90 days
Study: 10394686
Drug: Dihydroergocristine 1.5
Normalized name: dihydroergocristine 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergocristine 1.5 mg + Piracetam 0.8 g every 8 hours
Study: 8785138
Drug: Cis-atracurium 0.18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cis-atracurium 0.18 mg kg‐1 h‐1 (group 1, n = 6)
Study: 8785138
Drug: Atracurium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.6 mg kg‐1 h‐1 (group 2, n = 6)
Study: 6149589
Drug: Smoked marijuana
Normalized name: Picea mariana resin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoked marijuana (1 g cigarette containing 1.83% delta 9-THC)
Study: 6149589
Drug: Delta 9-THC
Normalized name: delta-9-THC
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delta 9-THC (17.5 mg)
Study: 6149589
Drug: Nabilone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabilone (2 mg orally)
Study: 29530271
Drug: Levothyroxine (LT4)
Normalized name: LT4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine (LT4) treatment; specific dosage and duration not mentioned.
Study: 11993621
Drug: CREATINE (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CREATINE (5 g of Cr, 4 times per day for 6 days)
Study: 11993621
Drug: PLACEBO (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLACEBO (same dosage of a glucose polymer)
Study: 9513799
Drug: Morphine (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (16 mg)
Study: 2153355
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (4 mg, 4 times daily for 4 months)
Study: 2153355
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (100 micrograms, 4 times daily for 4 months)
Study: 2153355
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 times daily for 4 months)
Study: 351886
Drug: Cadaver donor
Normalized name: Donor Human Stool
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadaver donor pretreatment with 5 g of methylprednisolone and 7 g of cyclophosphamide
Study: 25041383
Drug: Hydrogel patch
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogel patch applied directly on the affected area three times within the first 24 hours, followed by three additional patches over the next 3 days.
Study: 25041383
Drug: Hydrogel patch
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogel patch
Study: 21757278
Drug: Dextrose prolotherapy
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose prolotherapy (4 injections of 2 mL of 10% dextrose and 1 mL of 2% mepivacaine each 6 weeks apart)
Study: 21757278
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 injections of 2 mL of saline solution and 1 mL of 2% mepivacaine each 6 weeks apart)
Study: 19840635
Drug: Intracanal medication
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intracanal medication with 2% chlorhexidine gel (CHX)
Study: 19840635
Drug: Canal preparation
Normalized name: Canal + Gel 10% for Root Canal Preparation Dental Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canal preparation with 1.3% NaOCl
Study: 16759839
Drug: Meropenem 500
Normalized name: meropenem 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 500 mg every 8h
Study: 15373930
Drug: Monoclonal antibody
Normalized name: Monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibody ATM-027
Study: 9652559
Drug: Basiliximab (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basiliximab (20 mg infusion on day 0 and day 4)
Study: 3481627
Drug: Ofloxacin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (1 and 4 mg/l)
Study: 3481627
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of 400 mg ofloxacin with subsequent doses of 200 mg
Study: 31758735
Drug: Sofosbuvir 200
Normalized name: sofosbuvir 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir 200 mg/ledipasvir 45 mg (8-week treatment)
Study: 31758735
Drug: Sofosbuvir 200
Normalized name: sofosbuvir 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir 200 mg/ledipasvir 45 mg (12-week treatment)
Study: 20207825
Drug: GH plus
Normalized name: Pediacare Cough Plus Cold
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH plus raloxifene (R; 60 mg/d)
Study: 20207825
Drug: GH plus
Normalized name: Pediacare Cough Plus Cold
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH plus 17beta‐estradiol (E(2); 2 mg/d)
Study: 20207825
Drug: GH therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH therapy alone (0.5 mg/d)
Study: 12685518
Drug: Other stimulant
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other stimulant medications
Study: 12685518
Drug: Behavioral treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral treatments
Study: 7585848
Drug: Regimen A
Normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen A (contents from a 30‐mg capsule placed in a tablespoonful of applesauce)
Study: 2106837
Drug: UFT (1‐(2‐tetrahydrofuryl)‐5‐fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT (1‐(2‐tetrahydrofuryl)‐5‐fluorouracil mixed with uracil) orally at a daily dose of 300 mg
Study: 1164876
Drug: Dihydroergotamine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergotamine treatment
Study: 1164876
Drug: Dihydroergotamine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergotamine treatment (low-risk patients)
Study: 29178937
Drug: Levofloxacin 11
Normalized name: Levofloxacine
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin 11 mg/kg/day
Study: 29178937
Drug: Levofloxacin 14
Normalized name: Levofloxacine
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin 14 mg/kg/day
Study: 29178937
Drug: Levofloxacin 17
Normalized name: Levofloxacine
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin 17 mg/kg/day
Study: 29178937
Drug: Levofloxacin 20
Normalized name: levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin 20 mg/kg/day
Study: 29178937
Drug: Levofloxacin doses
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin doses (11, 14, 17, 20 mg/kg/day)
Study: 23948958
Drug: Low-dose/no statins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose/no statins
Study: 21930596
Drug: IH with
Normalized name: trenbolone acetate 80 mg / estradiol 8 mg / tylosin tartrate 29 mg SUBCUTANEOUS IMPLANT [Component TE-IH With Tylan]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IH with losartan (AT(1) receptor antagonist)
Study: 20061584
Drug: Gemfibrozil (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil (60 mg/kg/dose)
Study: 12160759
Drug: Iridium-192 intracoronary
Normalized name: iridium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iridium-192 intracoronary radiation therapy (IRT)
Study: 7955971
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily isophane (Protaphane)
Study: 7955971
Drug: Three times
Normalized name: WELLBUTRIN 100 MG Oral Tablet, Three Times Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three times daily soluble insulin (Actrapid)
Study: 7955971
Drug: Protaphane therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protaphane therapy
Study: 7955971
Drug: Actrapid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actrapid therapy
Study: 7955971
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy (both regimens)
Study: 3297124
Drug: Indomethacin (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (375 mg over 3 days)
Study: 3297124
Drug: Propranolol (circa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (circa 40 mg i.v. over 60 min)
Study: 3297124
Drug: VIP infusion
Normalized name: VIP
DrugBank: Vasoactive intestinal peptide (DB18634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIP infusion (6 pmol kg-1 min-1)
Study: 16680933
Drug: Diphenhydramine 50
Normalized name: diphenhydrAMINE 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine 50 mg, 3 times daily
Study: 16680933
Drug: Desloratadine 5
Normalized name: desloratadine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine 5 mg, once daily
Study: 9002102
Drug: C-aPDT vaccine
Normalized name: Meningococcal polysaccharide vaccine group C
DrugBank: Meningococcal polysaccharide vaccine group C (DB13890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-aPDT vaccine (Chiron/Biocine)
Study: 9002102
Drug: wDPT vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: wDPT vaccine (Connaught)
Study: 9002102
Drug: Lederle aPDT
Normalized name: Lederfen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lederle aPDT vaccine
Study: 3036724
Drug: sequential intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: sequential intermittent polychemotherapy (sq CT) after surgery
Study: 3036724
Drug: standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard chemotherapy (CT) after surgery
Study: 19515182
Drug: 3.9-5.0 mmol/l
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.9-5.0 mmol/l FPG target
Study: 19515182
Drug: 4.4-6.1 mmol/l
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.4-6.1 mmol/l FPG target
Study: 11231370
Drug: Furosemide 250
Normalized name: furosemide 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 250 mg every day
Study: 10095796
Drug: Quinapril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (20 mg once daily)
Study: 2905110
Drug: Piribedil (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piribedil (0.5 mg intravenously over 10 minutes)
Study: 27063071
Drug: Selexipag 400
Normalized name: SELEXIPAG 400MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selexipag 400 μg
Study: 27063071
Drug: Warfarin 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin 20 mg
Study: 23644932
Drug: Lutein (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein (10 mg) + Zeaxanthin (2 mg)
Study: 23644932
Drug: DHA (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA (350 mg) + EPA (650 mg)
Study: 18400776
Drug: Intravenous antivenom
Normalized name: ANTIVENIN,CROTALIDAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antivenom
Study: 18400776
Drug: Intramuscular antivenom
Normalized name: ANTIVENIN,CROTALIDAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular antivenom
Study: 15930213
Drug: Ibuprofen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (10 mg/kg, followed by 5 mg/kg after 24 and 48 hours)
Study: 12540788
Drug: 5-isosorbide mononitrate
Normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-isosorbide mononitrate (ISMN; 10 mg)
Study: 8800885
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with significant irrigant fluid absorption (peak breath alcohol > 300 mg/L) operated by consultant
Study: 8800885
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with significant irrigant fluid absorption (peak breath alcohol > 300 mg/L) operated by trainee
Study: 1815520
Drug: Prajmalium bitartrate
Normalized name: prajmalium bitartrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prajmalium bitartrate tablet (Neo‐Gilurytmal)
Study: 1815520
Drug: Oral solution
Normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution of prajmalium bitartrate
Study: 26387037
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic Acid (TA) - single dose of 20 mg/kg
Study: 16136031
Drug: Negative cytological
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative cytological preparations with positive HPV test
Study: 8729308
Drug: Esmolol 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol 1.5 mg.kg‐1
Study: 8729308
Drug: Lidocaine 1.5
Normalized name: LIDOCAINE 1.5%/EPI 1:200000 INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1.5 mg.kg‐1
Study: 30659292
Drug: Antioxidant treatment
Normalized name: OCTINOXATE 6 g in 100 g / AVOBENZONE 1.7 g in 100 g TOPICAL CREAM [Renewing Antioxidant Treatment SPF 6 GNLD International]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant treatment for 6 months (n=62)
Study: 30659292
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (n=28)
Study: 30659292
Drug: Antioxidant treatment
Normalized name: OCTINOXATE 6 g in 100 g / AVOBENZONE 1.7 g in 100 g TOPICAL CREAM [Renewing Antioxidant Treatment SPF 6 GNLD International]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant treatment (n=62)
Study: 29402680
Drug: No methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: No methadone treatment
Study: 25131184
Drug: 1.62% testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.62% testosterone gel (T-gel) for 6 months
Study: 25131184
Drug: 1.62% testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.62% testosterone gel (T-gel)
Study: 17461702
Drug: Acetaminophen 1
Normalized name: acetaminophen 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 1 g twice/day
Study: 17461702
Drug: Acetaminophen 4
Normalized name: acetaminophen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 4 g/day
Study: 17461702
Drug: Combined acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined acetaminophen groups
Study: 15114096
Drug: Vasosol (VSL)
Normalized name: phenylephrine / sulfacetamide sodium Ophthalmic Solution [Vasosulf]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasosol (VSL) machine perfusion solution
Study: 15114096
Drug: Control solution
Normalized name: Nausea Control Solution
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control solution (Belzer MPS)
Study: 17257280
Drug: Diazoxide, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazoxide, 100 mg at bedtime
Study: 1377741
Drug: Open treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open treatment phase
Study: 31466305
Drug: Maple products
Normalized name: coast maple pollen extract Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maple products (6% CHO solution)
Study: 31466305
Drug: Commercial sports
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial sports drink (6% CHO solution)
Study: 31466305
Drug: Glucose (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose (control CHO solution)
Study: 31466305
Drug: Water (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (control solution)
Study: 25619125
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) with lowest PAO quartiles
Study: 20626355
Drug: Intravenous ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ondansetron 4 mg at the end of surgery and 12 mg added to PCA (group O)
Study: 20626355
Drug: Intravenous ramosetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ramosetron 0.3 mg at the end of surgery and no antiemetics added to PCA (group R1)
Study: 20626355
Drug: Intravenous ramosetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ramosetron 0.3 mg at the end of surgery and 0.6 mg added to PCA (group R2)
Study: 17717627
Drug: 80 g
Normalized name: PEG-80 GLYCERYL COCOATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 g of mixed cruciferous vegetables
Study: 17717627
Drug: 350 g
Normalized name: ALCOHOL 350 g in 500 mL TOPICAL GEL [C2V LINE CLEAR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 350 g of mixed cruciferous vegetables
Study: 16310607
Drug: Subcutaneous unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous unfractionated heparin for routine thromboprophylaxis
Study: 16310607
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin for specific high-risk patients
Study: 12037271
Drug: Act‐Hib in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Act‐Hib in combination with BE DTwP (Group A, n = 160)
Study: 12037271
Drug: BE DTwP
Normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BE DTwP and Act‐Hib as separate injections (Group C, n = 58)
Study: 9873862
Drug: 3 MU
Normalized name: Orasep Reformulated Dec 2013 Mucosal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 MU of alpha interferon thrice weekly (TIW) for 3 months
Study: 9873862
Drug: Individualized dose
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized dose regimen tapering interferon dose from 3 or 6 MU by one-third every 2 months if transaminases were persistently normal
Study: 9873862
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose regimen (3 or 6 MU thrice weekly)
Study: 9873862
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (biochemical nonresponders followed for an additional 6 months)
Study: 31357748
Drug: nal-IRI monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: nal-IRI monotherapy